In multiple solid tumors, DAB2IP is clearly downregulated and its expression levels negatively correlate with tumor growth, angiogenesis, lymph node metastasis, advanced clinical stage, and resistance to therapies, establishing it function as a tumor suppressor [5–9]. This evidence concerns the gene DAB2IP and neoplasm.